NVUS - Novus Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.8882
+0.0052 (+0.59%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.8830
Open0.8600
Bid0.0000 x 1100
Ask0.0000 x 1400
Day's Range0.8590 - 0.9047
52 Week Range0.7430 - 7.8600
Volume73,412
Avg. Volume211,623
Market Cap11.455M
Beta (3Y Monthly)3.60
PE Ratio (TTM)N/A
EPS (TTM)-1.7130
Earnings DateAug 12, 2019 - Aug 19, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.75
Trade prices are not sourced from all markets
  • Investors Who Bought Novus Therapeutics (NASDAQ:NVUS) Shares A Year Ago Are Now Down 86%
    Simply Wall St.11 days ago

    Investors Who Bought Novus Therapeutics (NASDAQ:NVUS) Shares A Year Ago Are Now Down 86%

    It's not a secret that every investor will make bad investments, from time to time. But it's not unreasonable to try...

  • Business Wirelast month

    Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that data from OP0201 study C-002 will be presented during the 20th International Symposium on Recent Advances in Otitis Media, being held June 9-13, 2019 in Los Angeles, CA. Study C-002 was a phase 1 randomized, double-blind, placebo-controlled, parallel-group, dose-escalation clinical trial designed to evaluate safety and tolerability of 14 days of daily intranasal OP0201 (30 mg per day or 60 mg per day) compared to placebo in 30 healthy adults. The study was conducted at a single phase 1 unit in the United States.

  • Business Wire2 months ago

    Novus Therapeutics Reports First Quarter 2019 Financial Results

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter ended March 31, 2019.

  • Business Wire3 months ago

    Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the closing of its previously announced registered direct offering of 3,449,112 shares of its common stock, at a purchase price per share of $3.095, priced at-the-market, to healthcare-focused institutional investors, led by OrbiMed, BVF Partners L.P., and Armistice Capital. Novus also issued unregistered warrants to purchase up to 6,898,224 shares of common stock. The warrants were issued in two tranches.

  • Business Wire3 months ago

    Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 3,449,112 shares of its common stock, at a purchase price per share of $3.095, in a registered direct offering priced at-the-market. Additionally, Novus has also agreed to issue to the investors unregistered warrants to purchase up to 6,898,224 shares of common stock. The warrants are being issued in two tranches.

  • Business Wire3 months ago

    Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials

    The primary objective of establishing safety and tolerability was achieved in both healthy adults (study C-001) and in adults with acute otitis media (study C-004). “We are delighted that results from single-dose phase 1 studies met the primary objectives and demonstrated a favorable safety and tolerability profile,” said Dr. Catherine Turkel, President of Novus Therapeutics, “The safety profile of OP0201 was similar to placebo, and also similar when administered to healthy adults or adults with acute otitis media.

  • Business Wire4 months ago

    Novus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter and year ended December 31, 2018 and provided updates on the OP0201 development program.

  • Business Wire5 months ago

    Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate at the 8th Annual SVB Leerink Healthcare Conference on Thursday, February 28, 2019 at the Lotte New York Palace, New York. Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”).

  • Business Wire5 months ago

    Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first patients in a phase 2a trial of OP0201, the company’s lead product candidate being developed for otitis media. “We are pleased to be working with Dr. Alejandro Hoberman and the clinical research staff at the University of Pittsburgh on study C-006,” said Dr. Catherine Turkel, President of Novus Therapeutics. “Acute otitis media affects millions of people every year, particularly young children who account for more than half of the incident cases annually.

  • Business Wire5 months ago

    Company Profile for Novus Therapeutics, Inc.

    Novus Therapeutics, Inc. is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat . Novus has two technologies, each that has the potential to be developed for multiple ENT indications.

  • Business Wire5 months ago

    Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first adult subjects in study C-001, a phase 1 pharmacodynamics clinical trial of OP0201, the company’s lead product candidate being developed for otitis media. Dr. Catherine Turkel, President of Novus Therapeutics, stated, “In addition to collecting additional safety information, this study aims to explore the potential effect of OP0201 on Eustachian tube function as subjects are exposed to changes in atmospheric pressure.

  • Business Wire6 months ago

    Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials

    Screening Initiated for Phase 1 Pharmacodynamic Effects Trial

  • Business Wire6 months ago

    Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first adult patient with acute otitis media in a phase 1 clinical trial of OP0201, the company’s lead product candidate being developed for otitis media. “This phase 1 study will provide additional safety information in adults with acute otitis media and will help us better understand the onset of symptom relief following an initial dose of OP0201,” said Dr. Catherine Turkel, President of Novus Therapeutics. Study OP0201-C-004 (“C-004”) is a phase 1 clinical trial designed to evaluate safety and relief of ear pain following a single intranasal dose of OP0201 over a 60-minute observation period in 24 adults with acute otitis media.

  • Can We See Significant Institutional Ownership On The Novus Therapeutics, Inc. (NASDAQ:NVUS) Share Register?
    Simply Wall St.7 months ago

    Can We See Significant Institutional Ownership On The Novus Therapeutics, Inc. (NASDAQ:NVUS) Share Register?

    The big shareholder groups in Novus Therapeutics, Inc. (NASDAQ:NVUS) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own Read More...

  • Business Wire8 months ago

    Novus Therapeutics Announces Formation of Scientific Advisory Board

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the formation of a new Scientific Advisory Board (SAB), which is comprised of international experts in otolaryngology, pediatrics, and infectious diseases. The SAB will work closely with the Novus management team to advance OP0201, the company’s lead product candidate being developed for otitis media. “We are honored to have such a highly distinguished team of experts join our newly formed scientific advisory board,” said Dr. Catherine Turkel, President of Novus Therapeutics.

  • Business Wire8 months ago

    Novus Therapeutics Doses First Subjects in Phase 1 Study of OP0201

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first adult subjects in the low dose cohort of a phase 1 clinical trial of OP0201, the company’s lead product candidate being developed for otitis media. “The initiation of this phase 1 study represents a significant milestone for the company. Completion of this safety study will position us to quickly move forward and evaluate OP0201 in children with otitis media,” said Dr. Catherine Turkel, President of Novus Therapeutics.

  • Business Wire8 months ago

    Novus Therapeutics to Present at the 2018 Piper Jaffray Healthcare Conference

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that management will participate in the 30th Annual Piper Jaffray Health Care Conference to be held November 27-29, 2018 at the Lotte New York Palace. Gregory J. Flesher, CEO of Novus Therapeutics, is scheduled to present a company overview at 12:50 pm EST on Wednesday, November 28, 2018. Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”).

  • Business Wire8 months ago

    Novus Therapeutics Reports Third Quarter 2018 Financial Results

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter ended September 30, 2018.

  • Business Wire10 months ago

    Novus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), today announced that Gregory J. Flesher, Chief Executive Officer of Novus, will present at the Ladenburg Thalmann 2018 Healthcare Conference in New York City on Tuesday, October 2, 2018 at 9:30 AM Eastern Time.

  • Business Wire10 months ago

    Novus Therapeutics to Postpone Offering of Common Stock

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), today announced that it has elected to postpone the previously announced public offering of its common stock due to market conditions, including valuation sensitivity at the current share price. As of June 30, 2018, the company had $19.2 million in cash and cash equivalents. Novus believes that its current cash will be sufficient to achieve several key milestones in 2019, including completion of its planned phase 1 clinical trials with OP-02 in healthy adults, children with otitis media with effusion (“OME”), and adults with acute otitis media (“AOM”).

  • Business Wire11 months ago

    Novus Therapeutics Announces Proposed Public Offering of Common Stock

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. Novus expects to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 900,000 shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

  • Business Wire11 months ago

    Novus Therapeutics Reports Second Quarter 2018 Financial Results

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter ended June 30, 2018.